ReviewAtherosclerosis2017
Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.
Review in Atherosclerosis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 1 synthesis or guideline pooled it, 162 citations in OpenAlex.
- Intake of Soy, Soy Isoflavones and Soy Protein and Risk of Cancer Incidence and Mortality.Frontiers in nutrition · 2022Pooled it
- The intersection of colorectal cancer and cardiovascular disease: shared mechanisms and clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Cardiovascular Phenotypes Across Major Cancer Types: Distribution and Association with All-Cause Mortality in a Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Proteomics of multimorbidity progression across cardiometabolic diseases and cancer in a multinational cohort.Cardiovascular diabetology · 2026Article
- Metabolic and inflammatory biomarker trajectories after a cancer diagnosis and the risk of cardiovascular diseases.Nature communications · 2026Article
- Diagnostics in cardio-oncology: a focus on anthracyclines.Heart failure reviews · 2026Review
- Joint associations of multiple healthy lifestyles with the risk of cardiovascular disease: a prospective cohort study of UK Biobank.European journal of public health · 2026Article
- Pharmacological prevention in cardio-oncology: from bench-to-bedside.Heart failure reviews · 2025Review
- Inflammation Beyond the Prostate: The Role of Systemic Inflammatory Disorders in Prostate Carcinogenesis.Cureus · 2025Review
- Engineered immune-driven theranostics for clinical cardiology.Military Medical Research · 2025Review
- Elucidating the causal triad of cardiovascular disease, cancer, and lipid traits: a bidirectional Mendelian randomization study with genetic mediation analysis.Discover oncology · 2025Article
- Article
- Exploring the role of exosomal and non-exosomal non-coding RNAs in Kawasaki disease: Implications for diagnosis and therapeutic strategies against coronary artery aneurysms.Biochemistry and biophysics reports · 2025Review
- Insights Into Heart-Tumor Interactions in Heart Failure.Circulation research · 2025Review
- Taiwan Consensus for the Management of Cardiovascular Risks and Complications in Patients with Prostate Cancer.Acta Cardiologica Sinica · 2025Article
- Multivessel Coronary Artery Disease in Cancer Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2025Review
- Cancer, genetic susceptibility and risk of coronary artery disease: A prospective study.American journal of preventive cardiology · 2025Article
- Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin.Basic research in cardiology · 2025Article
- Effects of sex and obesity on immune checkpoint inhibition-related cardiac systolic dysfunction in aged mice.Basic research in cardiology · 2025Article
- Association of genetically proxied cancer-targeted drugs with cardiovascular diseases through Mendelian randomization analysis.Journal of translational medicine · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Cardiovascular disease (CVD) and cancer are leading causes of mortality and morbidity worldwide. Strategies to improve their treatment and prevention are global priorities and major focus of World Health Organization's joint prevention programs. Emerging evidence suggests that modifiable risk factors including diet, sedentary lifestyle, obesity and tobacco use are central to the pathogenesis of both diseases and are reflected in common genetic, cellular, and signaling mechanisms. Understanding this important biological overlap is critical and may help identify novel therapeutic and preventative strategies for both disorders. In this review, we will discuss the shared genetic and molecular factors central to CVD and cancer and how the strategies commonly used for the prevention of atherosclerotic vascular disease can be applied to cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.